FORMOSA LABORATORIES, INC.

Formosa Laboratories, Inc.

Company Presentation

TWSE 4746

FORMOSA LABORATORIES, INC.

Disclaimer

This material has been prepared by Formosa Laboratories Inc. (“Formosalab”).

Any opinions expressed in this material are subject to change without notice as a result of using different assumptions. Formosalab is under no obligation to update or keep current the information contained herein. The information contained in this presentation is Formosalab’s confidential information.

Any disclosure, copying, distribution or any action taken or omitted to be taken in reliance on it is prohibited and may be unlawful.

No representation or warranty, express or implied, is or will be made in or in relation to, and no responsibility or liability is or will be accepted by the Company as to, the accuracy or completeness of this material and any liability therefore is hereby expressly disclaimed.

Statements made in this material include forward-looking statements, which include, without limitation, statements about the issues, plans and expectations of Formosalab. Without limiting the foregoing, statements including the words “believes”, “anticipates”, “plans”, “expects” and similar expressions are also forward-looking statements. Forward-looking statements reflect, among other things, management’s plans and objectives for future operations, current views with respect to future events and future economic performances and projections of various financial items.

These forwardlooking statements involve known and unknown risks, uncertainties and other factors which may cause actual results to differ materially from those implied by such forward-looking statements.

FORMOSA LABORATORIES, INC.

Operation Results

FORMOSA LABORATORIES, INC.

2021 Sales

NTD M	**2021**	**YoY**
Polymers	1,204	0%
Vit. D Derivatives	606	3%
CDMO	140	-8%
Others	1,192	5%
Total	**3,142**	**2%**

5 years top line results



FORMOSA LABORATORIES, INC.

Product Mixture



Profitability

2021	
EPS	10.92
BP per share	61.50
Cash dividend	2.00



FORMOSA
LABORATORIES, INC.

Business Strategy

Integrated CDMO service



FORMOSA LABORATORIES, INC.

Partners for Key Areas

EirGenix 台康生技股份有限公司

ADC
Biosimilar

FORMOSA PHARMACEUTICALS, INC. 台新藥股份有限公司

Nano Tech
505(b)(2)

Protein
Drug
fill finish

API and Injectable

FORMOSA LABORATORIES, INC.

Access to Innovative Tech with Alliances

Nebulizer

hcmed

Amino Acid
Nuclide acid
mRNA

Global Quality System

Country/ Agency	First Inspection	Last Inspection
US FDA	2004	2018
Germany BGV	2007	2013
Japan PMDA	2009	2020
Mexico COFEPRIS	2010	2013
Europe EDQM	2013	*
Taiwan TFDA	2002	2021

- 46 products granted with GMP certificates
- 49 US DMF, 17 EU DMF、14 JMF，15 CN DMF and 8 COS
- Taiwan becomes a PIC/S member since 2013 and PIC/S members in principle will not need to inspect additionally

FORMOSA LABORATORIES, INC.

High Potent Facility

- Vit D derivatives
- Steroid hormones
- Anti-cancers
- ADCs

FORMOSA LABORATORIES, INC.

Fermentation Facility



FORMOSA
LABORATORIES, INC.

API Business

FORMOSA LABORATORIES, INC.

API Product Lines

- Anticancers
- Anti-inflammatory &Analgesic Agents
- MRI Enhancing Agents
- Respiratory Agents
- Polymeric Drugs
- CNS Agents
- Immunomodulators
- Steroids
- Vit. D Derivatives
- Antibiotics

Key Product Update

- **Polymers**
  - ✓ Sevelamer Carbonate & Sevelamer HCl
    - 20-30% Growth for 2022 in EU
    - 40-50% market share in the US
  - ✓ Colesevelam
    - 80% of the US market
    - Product launch in EU in 2022Q2
  - ✓ Colestipol
    - Exclusively supply to all approved generics companies except for AG, generics market share in the US ~ 99%
  - ✓ Strong market position with 40-70% share for all product lines in the world
  - ✓ Expansion to fit demand
- Chinese Market
  - ✓ Positive view with new product launches

CDMO full scale service



Strong CDMO Demand

- Strong income generation capability
- Clients including Big Pharma entered into efficacy confirmation and scale up stages, boosting demands
- Well developed ADC service platform for domestic and international clients with milestone supporting human trial and passing QP inspection
- Generated RD and manufacturing services up to formulation development and injection for any need against COVID-19 pandemic

ADC service



- One Stop Shop service from process development, scale up, analysis and fill finish

Strong ADC Demand

- Domestic and International Request
- Leading position in Taiwan for capability and capacity
- Line Expansion to meet demands

Batch Size	Client Region	Clinical Stage
00's g	APAC	Phase 2
00's g	Europe	Pre-clinical->Phase 1
00's mg	APAC	Pre-clinical
00's g	APAC	Phase 1
0's g	APAC	Pre-clinical
0's g	APAC	Pre-clinical

FORMOSA
LABORATORIES, INC.

Injectable DP

Global Standard Line

- NNE design
- USA(FDA), EMA and PMDA standard
- Serve small molecules and protein needs
- Regular line over 100M doses per anna.
- Cytotoxic line over several dozen M doses per anna.
- Eligible to support million doses for pre-clinical demand
- Scheduled inspection by government agents from 2021Q1 to 2022Q2
  - 2021Q3 cytotoxic line inspected by TFDA
  - 2021 granted with PICs GMP and PICs GDP certificates

Partner from DS to DP



FORMOSA LABORATORIES, INC.

台耀化學股份有限公司

Q&A